Nathan Fischel Net Worth

Nathan Fischel biography

Dr. Nathan Fischel M.D. serves as Director of the Company. He is the Founder and CEO of DAFNA Capital Management, LLC. DAFNA Capital is an SEC registered investment advisor with a highly successful investment track record of over 20 years focused on innovations in biotechnology and medical devices. Dr. Fischel was Professor of Pediatrics at UCLA School of Medicine, and attending physician in Pediatric Hematology and Oncology at Cedars-Sinai Medical Center in Los Angeles. He has published over 120 peer-reviewed scientific and medical manuscripts and book chapters, has been the principal investigator of multiple National Institutes of Health (“NIH”) funded research grants, has served repeatedly on internal and external review panels at the NIH, and was appointed by the U.S. Secretary of Health and Human Services to serve for four years on the Advisory Council of one of the NIH’s institutes. Dr. Fischel received his M.D. from the Technion Israel Institute of Technology and served his internship year at Hadassah Hospital in Jerusalem. He completed his residency and fellowship in Pediatrics and Pediatric Hematology and Oncology at the Children’s Hospital and the Dana-Farber Cancer Institute, Harvard Medical School in Boston, and his postgraduate research training in Molecular Genetics at Oxford University in England. Dr. Fischel’s experience as a physician enables him to provide critical perspectives regarding our technologies and commercial adoption of our products and his extensive knowledge of medical device companies allows him to provide insight to the Board on strategic decisions.

What is the salary of Nathan Fischel?

As the Director of Stereotaxis, the total compensation of Nathan Fischel at Stereotaxis is $240,300. There are no executives at Stereotaxis getting paid more.

How old is Nathan Fischel?

Nathan Fischel is 64, he's been the Director of Stereotaxis since 2017. There are 3 older and 6 younger executives at Stereotaxis. The oldest executive at Stereotaxis, Inc. is Robert Messey, 74, who is the Independent Director.

What's Nathan Fischel's mailing address?

Nathan's mailing address filed with the SEC is 4320 Forest Park Ave, St. Louis, MO 63108, USA.

Insiders trading at Stereotaxis

Over the last 6 years, insiders at Stereotaxis have traded over $16,447,723 worth of Stereotaxis stock and bought 502,585 units worth $872,120 . The most active insiders traders include Joe E Kiani, Paul J Isaac oraz Myriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of $124,591. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth $2,358.

What does Stereotaxis do?

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.

Stereotaxis executives and stock owners

Stereotaxis executives and other stock owners filed with the SEC include:

• Ross Levin,
  Independent Director
• Robert Messey,
  Independent Director
• Arun Menawat,
  Independent Director
• Joseph Kiani,
  Independent Director
• David Benfer,
  Lead Independent Director
• Nathan Fischel,
  Director
• David Fischel,
  Chairman of the Board, Chief Executive Officer
• Kimberly R. Peery,
  Chief Financial Officer
• Kimberly Peery,
  Chief Financial Officer
• Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• Guy Judkowski,
  Equity Portfolio Mang.
• Joe E Kiani,
  Director
• Paul J Isaac,
  Director
• Kevin M. Barry,
  Chief Legal Officer & Secretar
• Martin C Stammer,
  Chief Financial Officer
• Myriam Curet,
  Director